Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cells

Oncology Reports

Volumn 4, Issue 3, 1997, Pages 521-523

  Ohkoshi, Motohiro ^a   Denda, Tadamichi ^b   Hiwasa, Takaki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

human pancreatic carcinoma; MTT assay; ONO 3403; serine protease inhibitor

Indexed keywords

CAMOSTAT MESILATE; FO 349; ONO 3403; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0031004984     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.3.521     Document Type: Article

References (14)

1. Tamura Y, Hirano M, Okamura K, Minato Y and Fujii S: Synthetic inhibitor of trypsin, plasmin, kallikrein, thrombin, Cir Cl elastase. Biochim Biophys Acta 484: 417-422, 1977.
2. Ohkoshi M: Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl, 4-(4-guanidinobenzoyloxy) phenylacetate] methanesulfate. Jpn J Cancer Res 72: 959-964, 1981.
3. Ohkoshi M and Fujii S: Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl, 4-(4 guanidinobenzoyloxy)-phenylacetate]methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice. Jpn J Cancer Res 73: 108-110, 1982.
4. Ohkoshi M and Fujii S: Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin. J Natl Cancer Inst 71: 1053-1057, 1983.
5. Ohkoshi M, Akagawa T and Nakajima M: Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma. Anticancer Res 13: 963-966, 1993.
6. Hiwasa T, Tokita H, Hirose M, Ike Y and Ohkoshi M: Enhancement of anti-proliferative activities of 5-FU, HCFU, SN-38, THP and ACNU by a serine protease inhibitor, FOY-305. Int J Oncol 9: 517-520, 1996.
7. Senokuchi K, Nakai H, Nakayama Y, Odagaki Y, Sakaki K, Kato M, Maruyama T, Miyazaki T, Ito H, Kamiyasu K, Kim S, Kawamura M and Hamanaka N: New orally active serine protease inhibitors. J Med Chem 38: 2521-2523, 1995.
8. Hiwasa T and Ohkoshi M: Growth-suppressive activities of serine protease inhibitors, ONO-3403 and ONO-5046, toward normal and transformed murine fibroblasts. Anticancer Res 16: 1823-1826, 1996.
9. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
10. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
11. Mosmann TR and Fong TAT: Specific assays for cytokine production by T cells. J Immunol Methods 116: 151-158, 1989.
12. Hiwasa T, Soeda C, Takanohashi S, Kobayashi H, Suzuki A, Ueyama T and Ike Y: Screening of peptides which suppress the proliferation of transformed cells. Int J Oncol 8: 125-129, 1996.
13. Ohkoshi M and Oka T: Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouse and in treatment of terminal carcinoma. J Max-Fac Surg 12: 148-152, 1984.
14. Ohkoshi M: Protease inhibitors as anticancer drug: experimental and clinical study with serine protease inhibitors. In: Proteases Involved in Cancer. Suzuki M and Hiwasa T (eds). Monduzzi Editore, Bologna, pp125-127, 1995.